MHRA’s guidance on EU paediatric compliance
This article was originally published in Scrip
Before submitting a marketing authorisation to the UKMHRA, the agency strongly advises pharmaceutical companies to seek an opinion from theEMEA's paediatric committee on whether the application complies with the paediatric investigation plan (PIP), otherwise the MHRA itself will submit it to the committee.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.